Phenotypes associated with this allele

• Allele Symbol: Gt(ROSA)26Sor^tm1(Gck)Ydor
• Allele Name: targeted mutation 1, Yuval Dor
• Allele ID: MGI:5581726
• Summary: 4 genotypes

Jump to	Allelic Composition	Genetic Background	Genotype ID
cn1	Gt(ROSA)26Sor^tm1(Gck)Ydor/Gt(ROSA)26Sor^+ Trp53^tm1Brn/Trp53^tm1Brn Tg(Ins2-cre)25Mgn/0	involves: 129P2/OlaHsd * C57BL/6 * DBA	MGI:5581817
cn2	Gt(ROSA)26Sor^tm1(Gck)Ydor/Gt(ROSA)26Sor^tm1(Kcnj11*V59M)Fmas Tg(Pdx1-cre/Esr1*)#Dam/0	involves: 129S4/SvJae * C57BL/6 * CBA	MGI:5581815
cn3	Gt(ROSA)26Sor^tm1(Gck)Ydor/Gt(ROSA)26Sor^+ Tg(Pdx1-cre/Esr1*)#Dam/0	involves: C57BL/6 * CBA	MGI:5581813
cn4	Gt(ROSA)26Sor^tm1(Gck)Ydor/Gt(ROSA)26Sor^+ Tg(Ins2-cre)25Mgn/0	involves: C57BL/6 * DBA	MGI:5581816

Genotype
MGI:5581817

cn1

• Allelic Composition: Gt(ROSA)26Sor^tm1(Gck)Ydor/Gt(ROSA)26Sor⁺; Trp53^tm1Brn/Trp53^tm1Brn; Tg(Ins2-cre)25Mgn/0
• Genetic Background: involves: 129P2/OlaHsd * C57BL/6 * DBA

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

mortality/aging

postnatal lethality, incomplete penetrance ( J:210493 )

• some mice die before 3 weeks

homeostasis/metabolism

hyperglycemia ( J:210493 )

• slightly less so than in Gt(ROSA)26Sor^tm1(Gck)Ydor/Gt(ROSA)26Sor⁺ Tg(Ins2-cre)25Mgn mice

endocrine/exocrine glands

endocrine/exocrine gland phenotype ( J:210493 )

N • islet architecture and beta cells are preserved in newborns

Genotype
MGI:5581815

cn2

• Allelic Composition: Gt(ROSA)26Sor^tm1(Gck)Ydor/Gt(ROSA)26Sor^{tm1(Kcnj11*V59M)Fmas}; Tg(Pdx1-cre/Esr1*)#Dam/0
• Genetic Background: involves: 129S4/SvJae * C57BL/6 * CBA

endocrine/exocrine glands

abnormal pancreatic beta cell physiology ( J:210493 )

• beta cells from tamoxifen-treated mice exhibit signs of DNA damage and apoptosis compared to control mice but to a lesser extent than in mice lacking Gt(ROSA)26Sor^{tm1(Kcnj11*V59M)Fmas}

homeostasis/metabolism

hyperglycemia ( J:210493 )

• severe in tamoxifen-treated mice

Genotype
MGI:5581813

cn3

• Allelic Composition: Gt(ROSA)26Sor^tm1(Gck)Ydor/Gt(ROSA)26Sor⁺; Tg(Pdx1-cre/Esr1*)#Dam/0
• Genetic Background: involves: C57BL/6 * CBA

homeostasis/metabolism

decreased fasting circulating glucose level ( J:210493 )

• in tamoxifen-treated mice

• however, induced hypoglycemia is transient

increased circulating insulin level ( J:210493 )

• in tamoxifen-treated mice

increased oxygen consumption ( J:210493 )

• in tamoxifen-treated mice

endocrine/exocrine glands

abnormal pancreatic beta cell physiology ( J:210493 )

• increased beta cell apoptosis and reduced proliferation in tamoxifen-treated mice

• beta cells from tamoxifen-treated mice exhibit glucotoxicity including increased expression of ER and oxidative stress markers compared to in control cells

• however, GFP- beta cells exhibit increased proliferation and mice treated with a selective inhibitor of calcineurin (tacrolimus; FK-506) or a GLP-1 receptor agonist (liraglutide) exhibit reduced beta cell apoptosis and dysfunction

decreased pancreatic beta cell proliferation ( J:210493 )

• reduced proliferation in tamoxifen-treated mice

• however, GFP- beta cells exhibit increased proliferation

cellular

decreased pancreatic beta cell proliferation ( J:210493 )

• reduced proliferation in tamoxifen-treated mice

• however, GFP- beta cells exhibit increased proliferation

Genotype
MGI:5581816

cn4

• Allelic Composition: Gt(ROSA)26Sor^tm1(Gck)Ydor/Gt(ROSA)26Sor⁺; Tg(Ins2-cre)25Mgn/0
• Genetic Background: involves: C57BL/6 * DBA

mortality/aging

postnatal lethality, incomplete penetrance ( J:210493 )

• most mice die during the first week of life

homeostasis/metabolism

hyperglycemia ( J:210493 )

• at birth

decreased circulating insulin level ( J:210493 )

• mild at birth

endocrine/exocrine glands

decreased pancreatic beta cell mass ( J:210493 )

• reduced beta cell area at E16.5 and birth